



Quality For All

## Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Ramedda) S.A.E

PRESS RELEASE

### **Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Ramedda) S.A.E. acquires a sizeable molecule in a fast-growing therapeutic area**

**15 July 2021 | Cairo, Egypt**

Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Ramedda) S.A.E., (RMDA.CA on the EGX), a leading Egyptian pharmaceutical company, announced today that it has concluded the acquisition of an anticoagulant molecule as part of its previously communicated strategy to grow the company's portfolio through the purchase of existing molecules with an established market presence. The acquisition, which will be Ramedda's largest to date, enables the company to benefit from a large and fast-growing therapeutic area that has displayed a 3-year CAGR of c.67% between 2017 and 2020, and will take place in the form of a co-promotion agreement with the seller, whereas the Group will leverage the seller's sales team's extensive knowledge in the molecule and established sales network to continue to promote and sell the product through a pre-agreed commission scheme. The mechanics of the co-promotion agreement are yet to be finalized and will be shared with the market in due course.

-Ends-

#### **Investor Relations Contact:**

Yasmine Negm  
Ramedda's Head of Investor Relations & Strategic Communications  
Email: [yasmine.negm@rameda.com](mailto:yasmine.negm@rameda.com)  
Mobile: +20(0) 1228505050

#### **About Ramedda**

Established in 1986, Ramedda (RMDA.CA on EGX) is a leading Egyptian pharmaceutical company led by a team of professionals with extensive multinational experience. The company develops and produces a wide range of branded generic pharmaceuticals, nutraceuticals, food supplements and veterinary products. Ramedda combines global standards with local insights and a customer-centric approach. It has developed a broad portfolio of products across multiple therapeutic areas by successfully leveraging its strong product portfolio with its accretive product acquisitions to become one of the fastest-growing pharmaceutical players in Egypt. The company produces its wide range of dosage forms at its three manufacturing facilities located at its industrial complex in Cairo's Sixth of October Industrial Zone.

#### **Forward-Looking Statements**

This communication contains certain forward-looking statements. A forward-looking statement is any statement that does not relate to historical facts and events, and can be identified by the use of such words and phrases as "according to estimates", "anticipates", "assumes", "believes", "could", "estimates",



Quality For All

**Tenth of Ramadan for Pharmaceutical Industries  
and Diagnostic Reagents (Rameda) S.A.E**

PRESS RELEASE

“expects”, “intends”, “is of the opinion”, “may”, “plans”, “potential”, “predicts”, “projects”, “should”, “to the knowledge of”, “will”, “would”, or, in each case, their negatives, or other similar expressions that are intended to identify a statement as forward-looking. This applies, in particular, to statements containing information on future financial results, plans, or expectations regarding our business and management, our future growth or profitability and general economic and regulatory conditions and other matters affecting us.

Forward-looking statements reflect our management's (“Management”) current views of future events, are based on Management's assumptions, and involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by these forward-looking statements. The occurrence or non-occurrence of an assumption could cause our actual financial condition and results of operations to differ materially from, or fail to meet expectations expressed or implied by, such forward-looking statements. Our business is subject to a number of risks and uncertainties that could also cause a forward-looking statement, estimate, or prediction to become inaccurate. These risks include fluctuations in the prices of raw materials or employee costs required by our operations, its ability to retain the services of certain key employees, its ability to compete successfully, changes in political, social, legal, or economic conditions in Egypt, worldwide economic trends, the impact of war and terrorist activity, inflation, interest rate and exchange rate fluctuations, and Management's ability to timely and accurately identify future risks to our business and manage the risks mentioned above.

Certain figures contained in this document, including financial information, have been subject to rounding adjustments. Accordingly, in certain instances, the sum or percentage change of the numbers contained in this document may not conform exactly to the total figure given.